Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AC01 in Chronic Advanced Heart Failure With Reduced Ejection Fraction
NCT07584967Phase 2Not yet recruiting
- Sponsor
- AnaCardio
- Start
- Nov 2026
- Primary completion
- Jul 2028
- Modality
- Peptides, Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of AC01 in heart failure with reduced ejection fraction (HFrEF) (3 arms), sponsored by AnaCardio. Primary endpoint: Absolute Change from Baseline in Composite Echocardiography Z-Score at 12 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
AC01
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT07584967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07584967.